By Bhanvi Satija LONDON, April 29 (Reuters) - Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed ...

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc, Pfizer Inc. and other drugmakers to overturn a judge who allowed more than 80,000 lawsuits to proceed to trial ...

Back in April 2013, Focus covered a rather futuristic-sounding announcement from GlaxoSmithKline regarding its funding of a new field of medicine the company was calling "electroceuticals"-more ...

GSK (GSK) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.13 per share a year ago. These figures are ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Dec 12 (Reuters) - The European Medicines Agency has recommended the approval of GSK's (GSK.L), opens new tab add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said ...

GSK (GSK) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.09 per share a year ago. These figures are ...

GlaxoSmithKline (GSK) researchers at work in an R&D laboratory at the company's Stevenage, U.K., site. GSK has agreed to acquire Rapt Therapeutics for $2.2 billion, in a deal intended to bolster the ...